Scandinavian Biopharma has successfully completed the enrolment of their large Phase 2b trial in The Gambia
All participants have received the third and final vaccination dose in our large randomized, placebo-controlled, and double-blind phase 2b study in The Gambia. The study includes 4 936 children aged 6-18 months. The overall goal of the study is to investigate the efficacy against moderate to severe diarrhea caused by ETEC.